Few drugmakers translate cost cuts into efficiency
Have cost cuts made Big Pharma more efficient? By one financial measure--revenues per dollar of sales and administrative spending--not so much. Report
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Recipharm secures financing for future growth
- PPD Names David Simmons Chairman and CEO
- Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units
- PPD Names David Simmons Chairman and CEO
- NICE recommends new treatment option for people with common heart condition
- More Press Releases
Featured Jobs
-
Research & Development Chemist
C3 Jian - Marina Del Rey, CA -
Quality Assurance Scientist Job
Yoh - Brea, CA, USA -
Microbiology Scientist
C3 Jian - Marina Del Rey, CA -
Senior Scientist - Permanent Job
Yoh - Doylestown, PA, USA -
Associate Director, Manufacturing Operations Job
Celgene Corporation - Basking Ridge, NJ, US
Comments